| Title |
Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising Future
|
|---|---|
| Published in |
Pharmaceutical Research, September 2004
|
| DOI | 10.1023/b:pham.0000041444.06122.8d |
| Pubmed ID | |
| Authors |
Daniel H. van Raalte, Min Li, P. Haydn Pritchard, Kishor M. Wasan |
| Abstract |
Peroxisome proliferator-activated receptor (PPAR)-alpha is a ligand-activated transcriptional factor that belongs to the family of nuclear receptors. PPAR-alpha regulates the expression of genes involved in fatty acid beta-oxidation and is a major regulator of energy homeostasis. Fibrates are PPAR-alpha agonists and have been used to treat dyslipidemia for several decades because of their triglyceride (TG) lowering and high-density lipoprotein cholesterol (HDL-C) elevating effects. More recent research has demonstrated anti-inflammatory and anti-thrombotic actions of PPAR-alpha agonists in the vessel wall as well. Thus, PPAR-alpha agonists decrease the progression of atherosclerosis by modulating metabolic risk factors and by their anti-inflammatory actions on the level of the vascular wall. This is confirmed by several clinical studies, in which fibrates have shown to reduce atherosclerotic plaque formation and the event rate of coronary heart disease (CHD), especially in patients suffering from metabolic syndrome (MS). MS is characterized by a group of metabolic risk factors that include obesity, raised blood pressure, dyslipidemia, insulin resistance or glucose intolerance, and a prothrombotic state, and its incidence in the Western world is rising to epidemic proportions. This review paper will focus on the functions of PPAR-alpha in fatty acid beta-oxidation, lipid metabolism, and vascular inflammation. Furthermore, PPAR-alpha genetics, the clinical use of PPAR-alpha activators and their future perspective will be discussed. |
Mendeley readers
The data shown below were compiled from readership statistics for 163 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | <1% |
| Brazil | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Iraq | 1 | <1% |
| Unknown | 158 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 32 | 20% |
| Student > Bachelor | 28 | 17% |
| Researcher | 15 | 9% |
| Student > Master | 10 | 6% |
| Student > Doctoral Student | 9 | 6% |
| Other | 25 | 15% |
| Unknown | 44 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 32 | 20% |
| Biochemistry, Genetics and Molecular Biology | 24 | 15% |
| Medicine and Dentistry | 16 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 7% |
| Chemistry | 7 | 4% |
| Other | 27 | 17% |
| Unknown | 46 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2022.
All research outputs
#2,614,481
of 25,373,627 outputs
Outputs from Pharmaceutical Research
#116
of 2,982 outputs
Outputs of similar age
#3,933
of 69,940 outputs
Outputs of similar age from Pharmaceutical Research
#2
of 32 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,982 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 69,940 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.